Gleevec Decreases Cancer Recurrence for Patients with a Type of Gastrointestinal Cancer

New York,

Thursday, April 12, 2007

Memorial Sloan Kettering Cancer Center’s Ronald DeMatteo, MD, served as the principal investigator of a large cooperative group trial that found patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib (Gleevec ®) after complete removal of their tumor were significantly less likely to have a recurrence of the cancer compared to those who did not receive imatinib.

This study was funded by the National Cancer Institute

Add new comment

We welcome your questions and comments. While we share many of them with our world-class doctors and researchers, we regret that in order to protect your privacy, we are not able to make personal medical recommendations on this forum, nor do we publish comments that contain your personal information. If you would like to consult with an MSK doctor, we encourage you to make an appointment at 800-525-2225 or request an appointment online.

Your email address is kept private and will not be shown publicly.

Journalists may contact the Department of Public Affairs for more information.

Telephone: 212-639-3573